Cover Image
市場調查報告書

肺炎鏈球菌:開發中產品分析

Streptococcal Pneumonia - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 362370
出版日期 內容資訊 英文 139 Pages
訂單完成後即時交付
價格
Back to Top
肺炎鏈球菌:開發中產品分析 Streptococcal Pneumonia - Pipeline Review, H1 2016
出版日期: 2016年06月08日 內容資訊: 英文 139 Pages
簡介

本報告提供肺炎鏈球菌治療藥的開發情形相關調查,提供您開發中產品概要,各臨床實驗階段的產品概要,主要企業及藥物簡介,開發中產品的最新趨勢,及最新消息/新聞稿等資訊。

簡介

肺炎鏈球菌 (肺炎鏈球菌)的概要

治療藥的開發

肺炎鏈球菌:企業開發中的治療藥

肺炎鏈球菌:大學/機關研究中的治療藥

肺炎鏈球菌:開發中產品概況

肺炎鏈球菌:企業開發中的產品

肺炎鏈球菌:大學/機關研究中的產品

肺炎鏈球菌 (肺炎鏈球菌)的治療藥的開發企業

肺炎鏈球菌:治療藥的評估

藥物簡介

肺炎鏈球菌:最近的開發平台趨勢

肺炎鏈球菌:暫停中的計劃

肺炎鏈球菌:開發中止的產品

肺炎鏈球菌:產品開發的里程碑

附錄

目錄
Product Code: GMDHC8165IDB

Summary

Global Markets Direct's, 'Streptococcal Pneumonia - Pipeline Review, H1 2016', provides an overview of the Streptococcal Pneumonia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Streptococcal Pneumonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Streptococcal Pneumonia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Streptococcal Pneumonia
  • The report reviews pipeline therapeutics for Streptococcal Pneumonia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Streptococcal Pneumonia therapeutics and enlists all their major and minor projects
  • The report assesses Streptococcal Pneumonia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Streptococcal Pneumonia

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Streptococcal Pneumonia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Streptococcal Pneumonia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Streptococcal Pneumonia Overview
  • Therapeutics Development
  • Streptococcal Pneumonia - Therapeutics under Development by Companies
  • Streptococcal Pneumonia - Therapeutics under Investigation by Universities/Institutes
  • Streptococcal Pneumonia - Pipeline Products Glance
  • Streptococcal Pneumonia - Products under Development by Companies
  • Streptococcal Pneumonia - Products under Investigation by Universities/Institutes
  • Streptococcal Pneumonia - Companies Involved in Therapeutics Development
  • Streptococcal Pneumonia - Therapeutics Assessment
  • Drug Profiles
  • Streptococcal Pneumonia - Recent Pipeline Updates
  • Streptococcal Pneumonia - Dormant Projects
  • Streptococcal Pneumonia - Discontinued Products
  • Streptococcal Pneumonia - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Streptococcal Pneumonia, H1 2016
  • Number of Products under Development for Streptococcal Pneumonia - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Streptococcal Pneumonia - Pipeline by Abera Bioscience AB, H1 2016
  • Streptococcal Pneumonia - Pipeline by Actelion Ltd, H1 2016
  • Streptococcal Pneumonia - Pipeline by Alvogen Korea Co., Ltd., H1 2016
  • Streptococcal Pneumonia - Pipeline by Arsanis Biosciences GmbH, H1 2016
  • Streptococcal Pneumonia - Pipeline by AstraZeneca Plc, H1 2016
  • Streptococcal Pneumonia - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2016
  • Streptococcal Pneumonia - Pipeline by ContraFect Corporation, H1 2016
  • Streptococcal Pneumonia - Pipeline by Daiichi Sankyo Company, Limited, H1 2016
  • Streptococcal Pneumonia - Pipeline by Eurocine Vaccines AB, H1 2016
  • Streptococcal Pneumonia - Pipeline by FluGen, Inc., H1 2016
  • Streptococcal Pneumonia - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Streptococcal Pneumonia - Pipeline by ImmunoBiology Limited, H1 2016
  • Streptococcal Pneumonia - Pipeline by Lascco SA, H1 2016
  • Streptococcal Pneumonia - Pipeline by Liquidia Technologies, Inc., H1 2016
  • Streptococcal Pneumonia - Pipeline by Merck & Co., Inc., H1 2016
  • Streptococcal Pneumonia - Pipeline by Mucosis B.V., H1 2016
  • Streptococcal Pneumonia - Pipeline by Panacea Biotec Limited, H1 2016
  • Streptococcal Pneumonia - Pipeline by Prometheon Pharma, LLC, H1 2016
  • Streptococcal Pneumonia - Pipeline by Sanofi Pasteur SA, H1 2016
  • Streptococcal Pneumonia - Pipeline by Serum Institute of India Limited, H1 2016
  • Streptococcal Pneumonia - Pipeline by SK Chemicals Co., Ltd., H1 2016
  • Streptococcal Pneumonia - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016
  • Streptococcal Pneumonia - Pipeline by Valneva SE, H1 2016
  • Streptococcal Pneumonia - Pipeline by Vaxxilon AG, H1 2016
  • Streptococcal Pneumonia - Pipeline by Virometix AG, H1 2016
  • Streptococcal Pneumonia - Pipeline by Walvax Biotechnology Co., Ltd., H1 2016
  • Streptococcal Pneumonia - Pipeline by Wellstat Vaccines, LLC, H1 2016
  • Streptococcal Pneumonia - Pipeline by Wockhardt Limited, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Streptococcal Pneumonia Therapeutics - Recent Pipeline Updates, H1 2016
  • Streptococcal Pneumonia - Dormant Projects, H1 2016
  • Streptococcal Pneumonia - Dormant Projects (Contd..1), H1 2016
  • Streptococcal Pneumonia - Dormant Projects (Contd..2), H1 2016
  • Streptococcal Pneumonia - Dormant Projects (Contd..3), H1 2016
  • Streptococcal Pneumonia - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Streptococcal Pneumonia, H1 2016
  • Number of Products under Development for Streptococcal Pneumonia - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top